Barely Significant
← all excerpts

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study.

Cancers (Basel) · 2021 · PMC8471957 · PMID 34572958

Europe PMCDOI
1
hedged sentence
0.0800
closest p · 1.6× alpha
0.0800
boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)
As reported in the REGOMA trial, the subgroup of patients taking steroids at baseline showed a trend for a shorter survival compared to patients without steroid treatment, despite it not being statistically significant ( p = 0.08); indeed, the hazard ratio for patients receiving regorafenib and steroid was 0.75 versus 0.34 for patients treated with regorafenib alone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.